Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real‐life outcomes of daratumumab treatment

G Afram, C Gran, J Borg Bruchfeld… - European Journal of …, 2020 - Wiley Online Library
Background Little is reported on the real‐life impact of daratumumab in relapsed and/or
refractory multiple myeloma patients (RRMM). We analyzed a cohort of 156 patients who …
被引用次数：17 相关文章

Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment.

G Afram, C Gran, AK Wagner, A Hussain… - European Journal of …, 2020 - europepmc.org
Background Little is reported on the real-life impact of daratumumab in relapsed and/or
refractory multiple myeloma patients (RRMM). We analyzed a cohort of 156 patients who …

Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real‐life outcomes of daratumumab treatment.

G Afram, C Gran, J Borg Bruchfeld… - European Journal …, 2020 - search.ebscohost.com
Background: Little is reported on the real‐life impact of daratumumab in relapsed and/or
refractory multiple myeloma patients (RRMM). We analyzed a cohort of 156 patients who …
[PDF] academia.edu

[PDF][PDF] Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment

G Afram, C Gran, JB Bruchfeld, AK Wagner, A Hussain… - 2020 - academia.edu
Background: Little is reported on the real-life impact of daratumumab in relapsed and/or
refractory multiple myeloma patients (RRMM). We analyzed a cohort of 156 patients who …

Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment

G Afram, C Gran, JB Bruchfeld… - European journal …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Little is reported on the real-life impact of daratumumab in relapsed and/or
refractory multiple myeloma patients (RRMM). We analyzed a cohort of 156 patients who …
[PDF] researchgate.net

[PDF][PDF] Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment

G Afram, C Gran, JB Bruchfeld, AK Wagner, A Hussain… - 2020 - researchgate.net
Background: Little is reported on the real-life impact of daratumumab in relapsed and/or
refractory multiple myeloma patients (RRMM). We analyzed a cohort of 156 patients who …